ClinicalTrials.gg
RecruitingNCT07694076Updated Nov 3, 2026

Mechanisms of Repeated Real-time Biofeedback With 7-Tesla MRI in Depression

An interventional study of Active Biofeedback and Sham Biofeedback in Major Depressive Disorder (MDD), sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Oxford · Not applicable, Interventional, and Basic science

How we know

Updated Nov 3, 2026Start date movedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 96 studies in Depressive Disorder, Major with a site in United Kingdom — 16 open to participants now, 18 under way, 7 of them phase 3. Depressive Disorder, Major · United Kingdom.

Planned enrollment
55th of 84
60 · median 133
Started
2026
with 7 others
No phase
25 of 96
6 open now
Primary completion
2031-06
later than 17 of 17 live
Registered
90th of 96
by date
Lead sponsor
4 of 96
University of Oxford

Among the 96 studies in Depressive Disorder, Major with a site in United Kingdom, this one is the 55th largest by planned enrollment of the 84 interventional ones that give a count, is one of 8 that started in 2026, is one of 25 with no phase, reaches primary completion later than 17 of the 17 other live ones, and was the 90th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

16 of the 96 studies in Depressive Disorder, Major with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Depressive Disorder, Major with a site in United Kingdom, or all of them as a file.
02

Study summary

Previous work demonstrated that individuals are able to self-regulate their ventral tegmental area (VTA) activity using real-time biofeedback. The current study expands this approach to a larger sample with repeated training sessions to more robustly characterize the effects of VTA modulation. This mechanistic study will assess change in mood and motivation-related measures, as well as neural activity and connectivity changes.

Read the detailed description

Major depressive disorder (MDD) is one of the world's largest health problems with current treatments that are ineffective for a substantial proportion of individuals. There is a critical need for mechanistically informed interventions that are individualized and that aim to target core symptoms. Converging evidence from animal and human research in the field has implicated the ventral tegmental area (VTA), a key component of the brain's dopamine system, in regulating motivation and reward-related behaviour. Previous work has demonstrated that participants can successfully train to self-regulate their VTA activity using cognitive strategies while receiving real-time feedback. This shows that VTA self-regulation is feasible in humans. The current study builds on this previous work to further investigate the relationships between VTA activity modulation and mood and motivation related changes in individuals with MDD, in a mechanistic manner. Specifically, this study will aim to extend on prior findings by increasing the sample size and incorporating repeated training sessions. A total of 60 participants with MDD will be recruited and will be randomized in a 1:1 ratio to receive either active biofeedback or sham (control) feedback. Participants will complete two training sessions with real-time 7T-MRI biofeedback. During functional MRI (fMRI) scanning, participants will be trained to use self-generated cognitive strategies to modulate their VTA activity while viewing a visual representation of their brain signal (active condition) or a yoked control signal (sham condition). The primary objective of this study is to determine how variation in VTA modulation is associated with mood and motivation related mechanisms that might change over time. Secondary objectives include assessing changes in VTA activation and functional connectivity over time, as well as examining how neural changes relate to mood and motivation-related changes.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • Brain imaging
  • Biofeedback
  • 7-Tesla MRI
  • Depression
  • Dopamine
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18-65 years;
  • Meets criteria for major depressive disorder (MDD) as determined by the Structured Clinical Interview for DSM-5 Axis Disorders (SCID) or the Mini International Neuropsychiatric Interview (MINI); with a current major depressive episode; as conducted in a research-based non-clinical setting.
  • Participants must have a level of understanding of the English language sufficient to agree to all tests and examinations required by the study and must be able to participate fully in the process.

Exclusion criteria

Exclusion Criteria:

  • Current or history of schizophrenia or other psychotic disorder, neurodevelopmental disorder, neurocognitive disorder or cognitive impairment
  • Active substance use disorder within the past 1 year;
  • Any unstable medical illnesses;
  • Women who are pregnant;
  • Any to MRI
  • Antidepressant medication initiated within 2 weeks of the Baseline Assessment and concomitant use of any other medication with central nervous system activity during active participation;
  • Active suicidal intent or plan.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active Biofeedback

    The participants in the active group will receive repeated active biofeedback training sessions.

    Behavioral: Active Biofeedback

  • Sham comparator
    Sham Biofeedback

    The participants in the sham group will receive repeated sham biofeedback training sessions.

    Behavioral: Sham Biofeedback

Interventions

  • BehavioralActive Biofeedback

    The active biofeedback session will be done within the 7T MRI. It will include MOTIVATE and active rest trials. During each MOTIVATE trial, subjects will be instructed to generate a heightened state of motivation. Subjects will simultaneously view a progress bar on the screen during MOTIVATE trials that represents their VTA activity and they will be trained to try to increase the level of the bar by motivating themselves.

  • BehavioralSham Biofeedback

    The sham biofeedback session resembles the active condition, however, the progress bar seen during the MOTIVATE trials will represent yoked sham values.

06

What researchers measure

Primary outcomes

  1. Mood and Motivation Related Mechanistic Measures

    A single composite metric will be derived by factor analysis of a battery of validated mood and motivation related instruments (e.g. PANAS-SF, POMS-SF, MAP-SR), providing one expected latent mood and motivation factor. Modelling the instruments jointly avoids nominating any single scale as the mechanistic outcome, and controls for multiple comparisons. Unit of measure: standardized latent factor score (z / SD units).

    Time frame: Pre to post biofeedback training, within a 6-week timeframe.

  2. VTA Connectivity

    Functional connectivity between the VTA seed and whole-brain (voxelwise), measured with 7-Tesla fMRI. Unit of measure: Fisher z-transformed correlation coefficient.

    Time frame: Pre to post biofeedback training, within a 4-week timeframe.

Secondary outcomes

  1. VTA Activation

    Blood-oxygen-level-dependent (BOLD) signal in the bilateral ventral tegmental area (VTA) region of interest for MOTIVATE versus active rest trials, measured with task-based 7-Tesla fMRI. Unit of measure: percent BOLD signal change.

    Time frame: Pre to post biofeedback training, within a 4-week timeframe.

  2. Association between change in VTA measures and change in the mood and motivation factor

    The standardized VTA activation and connectivity measure will each be tested for an association with change in the mood and motivation factor. One coefficient is reported per VTA measure. Unit of measure: standardized regression coefficient (dimensionless, from -1 to 1).

    Time frame: Pre to post biofeedback training, within a 6-week timeframe.

Other outcomes

  1. Mood and Motivation EMA

    Single-item mood and motivation ecological momentary assessment (EMA). Unit of measure: arbitrary likert rating.

    Time frame: Pre to post biofeedback training, within a 6-week timeframe.

07

Study locations

1 of 1 sites recruiting
  • Oxford Centre for Integrative Neuroimaging (OxCIN) FMRIB, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital
    Oxford, OX39DU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2031, 54 months later.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 54 months is above that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2026
First posted
Jul 9, 2026
StartEst.
Dec 2026was Jun 2026
Primary completionEst.
Jun 2031
CompletionEst.
Jun 2033
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Dec 2026
Nov 3, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedMeets DSM-5 criteria for major depressive disorder (MDD) as determined by the Structured Clinical Interview for DSM-5 Axis Disorders (SCID) or the Mini International Neuropsychiatric Interview (MINI); with a current major depressive episode; as conducted in a research-based non-clinical setting.
Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedMood and Motivation Related Mechanistic MeasuresTime frame: Pre to post biofeedback training, within a 6-week timeframe.
Nov 3, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • Descriptionother outcomeMood and Motivation EMA: how it is measured was reworded
Nov 3, 2026
Title
Mechanisms of Repeated Real-time Biofeedback With 7-Tesla MRI for Treatment ofin Depression
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Start date Jun 2026→Dec 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedMeets DSM-5 criteria for major depressive disorder (MDD) as determined by the Structured Clinical Interview for DSM-5 Axis Disorders (SCID) or the Mini International Neuropsychiatric Interview (MINI); with a current major depressive episode; as conducted in a research-based non-clinical setting.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedMood and Motivation Related Mechanistic MeasuresTime frame: Pre to post biofeedback training, within a 6-week timeframe.
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • Descriptionother outcomeMood and Motivation EMA: how it is measured was reworded
    Title Mechanisms of Repeated Real-time Biofeedback With 7-Tesla MRI for Treatment ofin Depression
    + 2 other changes: description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07694076
Collaborators
Wellcome Trust
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2031 (estimated)
Completion
Jun 2033 (estimated)
Last update
Nov 3, 2026

Study contacts

Laurel S Morris, Dr
Contact
laurel.morris@ndcn.ox.ac.uk
01865 (6)16577
Laurel S Morris, Dr
principal investigator · University of Oxford

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion